Detail akcie Aurinia Pharma online

Business Summary: Aurinia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. It sells LUPKYNIS to specialty pharmacies and a specialty distributor in the United States and sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. (Otsuka), for the European and Japanese market. The Company sells encapsulated voclosporin to its collaboration partner, Otsuka, which Otsuka then sells to customers in its territories.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Aurinia Pharmaceuticals Inc revenues increased 23% to $132.5M. Net income totaled $44.9M vs. loss of $10M. Revenues reflect Revenue Sales of Goods & Services increase from $4.4M to $69.1M. Net Income reflects Labor & Related Expenses in SGA decrease of 45% to $22.1M (expense), Stock-based Compensation in SGA decrease of 91% to $1.4M (expense), Corponess d decrease of 38% to $22.8M (expense).